June 12, 2025
  • Facebook
  • Twitter
  • LinkedIn

BiomolBiomed Viewpoints

Science in plain words

  • Home
  • News
  • About
    • BiomolBiomed Viewpoints
    • BiomolBiomed Journal
  • Journal Website
  • Reviews
  • pathology
  • microbiology
  • immunology
  • translational medicine
  • genetics
  • biochemistry
  • anatomy
  • molecular biology
  • clinical medicine
  • new methods
  • new medical entities
Latest posts
  • [ June 11, 2025 ] New Clues to Treating Aortic Dissection: Targeting ERBB4 for Vascular Repair Author Summary
  • [ June 9, 2025 ] Skin Changes May Help Diagnose ALS Earlier Author Summary
  • [ June 4, 2025 ] TCF12 Enhances Liver Cancer Angiogenesis and Drug Response via HIF-1α Author Summary
  • [ June 4, 2025 ] The Reviewer of the Month for June 2025: Dr. Zulcaif Ahmad, PhD Reviewer of the Month
  • [ June 2, 2025 ] Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer Author Summary
Homeimmunotherapy

immunotherapy

Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer
Author Summary

Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer

June 2, 2025 0

Shorter Surgery Gap, Better Outcomes: New Insights into Immunochemotherapy for Esophageal Cancer A Look into New Treatment Strategies for a Difficult Disease Esophageal cancer (EC) is among the most aggressive and deadly cancers worldwide. It […]

The Reviewer of the Month for August 2024: Takahiro Tsujikawa, MD, PhD
Reviewer of the Month

The Reviewer of the Month for August 2024: Takahiro Tsujikawa, MD, PhD

August 12, 2024 0

Peer review is crucial in the scientific publishing process, as it ensures that research papers meet high-quality and accurate standards. Each month, the BiomolBiomed Editorial team recognizes a reviewer who has delivered outstanding and constructive […]

Unlocking Immunotherapy Success: How Hematological Parameters Predict Outcomes in Advanced Non-Small Cell Lung Cancer
Author Summary

Unlocking Immunotherapy Success: How Hematological Parameters Predict Outcomes in Advanced Non-Small Cell Lung Cancer

August 7, 2024 0

Lung cancer is the leading cause of cancer-related deaths globally, with nearly 2.5 million new cases annually. Non-small cell lung cancer (NSCLC) accounts for approximately 80%–85% of all lung cancer cases. Most patients are diagnosed […]

New biomarkers for predicting low-grade glioma prognosis
Author Summary

New biomarkers for predicting low-grade glioma prognosis

December 5, 2022 0

Low-grade glioma (LGG) belongs to a large class of gliomas, tumors that occur in the brain and spinal cord, with great intrinsic heterogeneity. In recent years, in-depth studies of the tumor microenvironment have made a […]

Colorectal cancer patients may benefit from dual-drug immunotherapy
Author Summary

Colorectal cancer patients may benefit from dual-drug immunotherapy

November 28, 2022 0

Colorectal cancer is the 3rd most common cancer worldwide. Immunotherapy has been shown to be therapeutically effective in patients with colorectal cancer who have significant levels of microsatellite instability (regions of repeated DNA that change […]

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype
News

Microsatellite instability status predicts response to anti-PD-L1 therapy regardless the histotype

July 22, 2017 0

Le et al. recently reported (Science 10.1126/science.aan6733 (2017); (ClinicalTrials.gov number, NCT01876511) on the success of immune checkpoint blockade with anti-PD-1 antibodies in the patients whose cancers exhibited microsatellite instability-high (MSI-H) status. The study included 12 […]

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors
News

Recent advances in cancer immunotherapy based in immune checkpoint inhibitors

June 9, 2017 0

Targeted therapy based on the immune checkpoint inhibitors (Anti-PD1/PD-L1) has revolutionized cancer treatment and outcome of several solid and hematologic malignancies, including non-small cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, metastatic malignant melanoma, advanced/metastatic […]

VIDEO INTERVIEWS

VIDEO SUMMARIES

BiomolBiomed journal metrics

  • Impact Factor 2023 (JCR®): 3.1
  • CiteScore 2023 (Scopus): 7.4
  • Google Scholar Citations
  • Dimensions metrics

See more here…

pathriver logo
next generation pathology

BiomolBiomed Newsletters

Subscribe to receive the latest content and news from Biomolecules and Biomedicine. Choose from our sections or themes of your interest.

Categories

  • Author Summary
  • Conferences
  • Interview
  • News
  • Opinion
  • Reviewer of the Month
  • Topics
  • Video Summary

Archives

TELL US

What matters the most when choosing the journal to submit your article?
Vote
Follow us on Facebook

Copyright (c) 2021 Association of Basic Medical Sciences of FBIH

 

Loading Comments...